Physician profile
Sydney Stoops
NPI 1710640149
$1,634.03
in general payments reported to CMS, 2019-2025
32 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $985 · 2024: $356 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.35 |
| Education | $113.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $131.22 | 2022-2024 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $125.00 | 2023 | Darzalex, Tecvayli, Erleada |
| Novartis Pharmaceuticals Corporation | $104.47 | 2022-2024 | |
| Pfizer INC. | $92.48 | 2023-2024 | |
| Daiichi Sankyo INC. | $91.71 | 2023-2024 | Enhertu, Injectafer |
| Celgene Corporation | $90.49 | 2023-2024 | Reblozyl, Pomalyst |
| Abbvie INC. | $77.72 | 2025 | |
| Janssen Pharmaceuticals, INC | $74.65 | 2023-2024 | Xarelto |
| Genzyme Corporation | $74.57 | 2023 | |
| Lilly USA, LLC | $63.81 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Exact Sciences Corporation | $58.73 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $50.13 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $47.14 | 2023-2024 | Libtayo |
| Amgen INC. | $46.51 | 2023 | Lumakras |
| Genentech USA, INC. | $46.42 | 2022-2023 | Venclexta, Tecentriq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $43.87 | 2023 | Padcev |
| Astrazeneca Pharmaceuticals Lp | $43.25 | 2025 | Enhertu |
| Janssen Scientific Affairs, LLC | $40.61 | 2023 | Xarelto |
| Taiho Oncology, INC. | $39.39 | 2023 | |
| Jazz Pharmaceuticals INC. | $34.60 | 2024 | |
| Sumitomo Pharma America, INC. | $34.51 | 2023-2024 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $31.33 | 2023 | Opdivo |
| Astellas Pharma US INC | $28.10 | 2024 | |
| Genmab U.S., INC. | $27.48 | 2023 | Tivdak |
| Tempus Ai, INC | $20.78 | 2024 | |
| Incyte Corporation | $20.58 | 2023 | Jakafi |
| Aveo Pharmaceuticals, INC. | $20.53 | 2023 | Fotivda |
| Sobi, INC | $18.19 | 2022 | |
| Mirati Therapeutics, INC. | $15.86 | 2024 | Krazati |
| Novo Nordisk INC | $13.80 | 2025 | Wegovy |
| Eisai INC. | $13.18 | 2022 | |
| Array Biopharma INC | $12.92 | 2023 | Paxlovid, Mektovi, Prevnar 20 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Stoops listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.